Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Evandro de Azambuja

Showing results (61-70 of 299) with videos related to

Pageof 30
Sort By:
The Oncologist|February 16, 2006
Breast cancer: achievements in adjuvant systemic therapies in the pre-genomic eraMariantonietta Colozza, Evandro de Azambuja, Fatima Cardoso, et al.
Expert Review of Anticancer Therapy|June 16, 2020
Metronomic chemotherapy combined with endocrine therapy: are we challenging some dogmas?Rafael Caparica, Claudia De Angelis, Ângelo Fêde, et al.
Hematology/Oncology Clinics of North America|May 22, 2007
Trastuzumab (herceptin) for early-stage breast cancerGustavo Ismael, Daniela Dornelles Rosa, Evandro de Azambuja, et al.
Clinical Breast Cancer|May 14, 2023
Corrigendum to "Prognostic and predictive impact of beta-2 adrenergic receptor expression in HER2-positive breast cancer" [Clin Breast Cancer 2020; 20:262-73.e7]Rafael Caparica, François Richard, Mariana Brandão, et al.
Breast Cancer Research and Treatment|November 23, 2018
Anthracycline and taxane-based chemotherapy versus docetaxel and cyclophosphamide in the adjuvant treatment of HER2-negative breast cancer patients: a systematic review and meta-analysis of randomized controlled trialsRafael Caparica, Marco Bruzzone, Francesca Poggio, et al.
Cancer Treatment Reviews|June 14, 2020
HER2-positive advanced breast cancer treatment in 2020Marcelle G Cesca, Lucas Vian, Sofia Cristóvão-Ferreira, et al.
Therapeutic Advances in Medical Oncology|March 6, 2019
Post-neoadjuvant treatment and the management of residual disease in breast cancer: state of the art and perspectivesRafael Caparica, Matteo Lambertini, Noam Pondé, et al.
Plos One|March 15, 2017
Are life-saving anticancer drugs reaching all patients? Patterns and discrepancies of trastuzumab use in the European Union and the USAFelipe Ades, Christelle Senterre, Dimitrios Zardavas, et al.
Oncology Research and Treatment|January 15, 2023
Medical Oncology Education in Europe: Equipping Medical Oncologists to Provide the Best Care for Patients with CancerKarin Jordan, Evandro De Azambuja, Teresa Amaral, et al.
European Journal of Cancer (Oxford, England : 1990)|January 11, 2020
Trastuzumab emtansine (T-DM1)-associated cardiotoxicity: Pooled analysis in advanced HER2-positive breast cancerNoam Pondé, Lieveke Ameye, Matteo Lambertini, et al.
Pageof 30

Showing results (61-70 of 299) with videos related to

Sort By:
Pageof 30
The Oncologist|February 16, 2006
Breast cancer: achievements in adjuvant systemic therapies in the pre-genomic eraMariantonietta Colozza, Evandro de Azambuja, Fatima Cardoso, et al.
Expert Review of Anticancer Therapy|June 16, 2020
Metronomic chemotherapy combined with endocrine therapy: are we challenging some dogmas?Rafael Caparica, Claudia De Angelis, Ângelo Fêde, et al.
Hematology/Oncology Clinics of North America|May 22, 2007
Trastuzumab (herceptin) for early-stage breast cancerGustavo Ismael, Daniela Dornelles Rosa, Evandro de Azambuja, et al.
Clinical Breast Cancer|May 14, 2023
Corrigendum to "Prognostic and predictive impact of beta-2 adrenergic receptor expression in HER2-positive breast cancer" [Clin Breast Cancer 2020; 20:262-73.e7]Rafael Caparica, François Richard, Mariana Brandão, et al.
Breast Cancer Research and Treatment|November 23, 2018
Anthracycline and taxane-based chemotherapy versus docetaxel and cyclophosphamide in the adjuvant treatment of HER2-negative breast cancer patients: a systematic review and meta-analysis of randomized controlled trialsRafael Caparica, Marco Bruzzone, Francesca Poggio, et al.
Cancer Treatment Reviews|June 14, 2020
HER2-positive advanced breast cancer treatment in 2020Marcelle G Cesca, Lucas Vian, Sofia Cristóvão-Ferreira, et al.
Therapeutic Advances in Medical Oncology|March 6, 2019
Post-neoadjuvant treatment and the management of residual disease in breast cancer: state of the art and perspectivesRafael Caparica, Matteo Lambertini, Noam Pondé, et al.
Plos One|March 15, 2017
Are life-saving anticancer drugs reaching all patients? Patterns and discrepancies of trastuzumab use in the European Union and the USAFelipe Ades, Christelle Senterre, Dimitrios Zardavas, et al.
Oncology Research and Treatment|January 15, 2023
Medical Oncology Education in Europe: Equipping Medical Oncologists to Provide the Best Care for Patients with CancerKarin Jordan, Evandro De Azambuja, Teresa Amaral, et al.
European Journal of Cancer (Oxford, England : 1990)|January 11, 2020
Trastuzumab emtansine (T-DM1)-associated cardiotoxicity: Pooled analysis in advanced HER2-positive breast cancerNoam Pondé, Lieveke Ameye, Matteo Lambertini, et al.
Pageof 30